Medication info
Clopidogrel Tablet (Clopidogrel Bisulfate)

Clopidogrel Tablet (Clopidogrel Bisulfate)

Prescription medicationTablet
Ingredient · strength
Clopidogrel Bisulfate›97.875mg / 1 tablet
Manufacturer / importer
Hanmi Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201500929 · Approved 2015.02.24 · Insurance code 657202790

Summary

Main use
Improvement of atherosclerotic conditions (including acute coronary syndrome) and prevention of thromboembolism in atrial fibrillation
Who uses it
Adults
Adult dosage
○ Adults 1. For patients with ischemic stroke, myocardial infarction, or peripheral arterial disease, administer clopidogrel 75 mg orally once daily. 2. For patients with acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), begin treatment on the day this drug is initiated with a loading dose of 300 mg once daily, followed by a maintenance dose of 75 mg once daily, administered orally. Aspirin 75 ∼ 325 mg should be coadministered with this drug once daily. 3. For patients with atrial fibrillation, administer this drug 75 mg orally once daily. Aspirin 75 ~ 100 mg should be coadministered with this drug once daily. ○ Patients with renal impairment: Experience with treatment in patients with renal impairment is limited. ○ Patients with hepatic impairment: Experience with treatment in patients with moderate liver disease and a bleeding diathesis is limited. This drug may be administered with or without food.

Ingredients

Manufacturer
Hanmi Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of atherosclerotic conditions (including acute coronary syndrome) and prevention of thromboembolism in atrial fibrillation

  • Ischemic stroke
  • myocardial infarction
  • peripheral arterial disease
  • acute coronary syndrome
  • unstable angina
  • non-Q wave myocardial infarction
  • cardiovascular anomalies
  • stroke
  • refractory ischemia
  • vascular risk factors
  • atrial fibrillation
  • atherothrombosis
View approved original text

This medication is used to improve symptoms caused by atherosclerosis in adults with ischemic stroke, myocardial infarction, or peripheral arterial disease. Additionally, it helps to reduce the risk of cardiovascular complications and alleviate symptoms in patients with acute coronary syndrome who have received drug therapy, coronary intervention, or coronary artery bypass surgery for unstable angina or non-Q wave myocardial infarction. Furthermore, it improves health by reducing the risk of thromboembolism, including stroke, in patients with atrial fibrillation who have one or more vascular risk factors, cannot use vitamin K antagonists, and have a low risk of bleeding. In summary, this medication is effectively used to prevent and treat vascular complications.

Dosage and Administration

Adult dosage

○ Adults 1. For patients with ischemic stroke, myocardial infarction, or peripheral arterial disease, administer clopidogrel 75 mg orally once daily. 2. For patients with acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), begin treatment on the day this drug is initiated with a loading dose of 300 mg once daily, followed by a maintenance dose of 75 mg once daily, administered orally. Aspirin 75 ∼ 325 mg should be coadministered with this drug once daily. 3. For patients with atrial fibrillation, administer this drug 75 mg orally once daily. Aspirin 75 ~ 100 mg should be coadministered with this drug once daily. ○ Patients with renal impairment: Experience with treatment in patients with renal impairment is limited. ○ Patients with hepatic impairment: Experience with treatment in patients with moderate liver disease and a bleeding diathesis is limited. This drug may be administered with or without food.

Precautions

This medication prevents platelets in the blood from clumping together, allowing blood to flow more easily. The medication needs to be converted into its active form in the liver to be effective; those with genetic deficiencies in the enzymes that activate this medication may experience reduced effectiveness. Since there is a risk of bleeding while taking this medication, it may take longer than usual for bleeding to stop. You should be aware that if bleeding occurs or worsens at the site, you must inform your doctor immediately. Patients at high risk of bleeding or those who are already experiencing bleeding should be cautious when taking this medication. Especially those with bleeding disorders such as gastrointestinal, intracranial bleeding, severely impaired liver function, breastfeeding women, or those with lactose intolerance should not take this medication. If bleeding or blood abnormalities are suspected, prompt testing is necessary, and you should be cautious of increased bleeding risks when taking this medication alongside other antiplatelet or anticoagulant agents. Patients scheduled for surgery should stop taking this medication 5 to 7 days prior and resume only after hemostasis is achieved. Taking this medication with aspirin may increase the risk of bleeding, so you should follow your doctor’s instructions if combining them. This medication can rarely cause severe thrombocytopenia or blood disorders; thus, if fever or signs of infection occur, you should consult with healthcare professionals. Some patients may experience skin rashes or allergic reactions, so report any unusual symptoms. While the risk to the fetus during pregnancy is not significant, the risk of bleeding during delivery may increase, so you should stop taking it before childbirth. For breastfeeding individuals, since this medication may pass into breast milk, you should consult with your doctor about whether to continue or discontinue breastfeeding. Elderly patients or those with impaired kidney and liver function are at increased risk of bleeding, necessitating dosage adjustments and monitoring. Overdosing on this medication may significantly increase the risk of bleeding, and because there is no specific antidote, platelet transfusion may be needed if bleeding occurs. The safety and efficacy of this medication in children have not been established, therefore its use is not recommended. This medication may interact with other drugs, so it is essential to inform your doctor or pharmacist about any other medications you are taking. Particularly, caution is needed when taking it with drugs that may increase bleeding risk or interfere with its metabolism in the liver.

Side effects

  • Hemorrhage
  • gastrointestinal bleeding
  • purpura
  • contusion
  • hematoma
  • epistaxis
  • hematuria
  • intraocular hemorrhage
  • intracranial hemorrhage
  • severe neutropenia
Show 87 more
  • aplastic anemia
  • thrombocytopenia
  • gastrointestinal symptoms
  • abdominal pain
  • dyspepsia
  • diarrhea
  • nausea
  • rash
  • pruritus
  • chest pain
  • accidental injury
  • influenza-like illness
  • pain
  • fatigue
  • edema
  • hypertension
  • headache
  • dizziness
  • depression
  • dyspnea
  • rhinitis
  • bronchitis
  • cough
  • urinary tract infection
  • decreased motor function
  • tremor
  • voice disorder
  • abnormal gait
  • hyperkinesis
  • ataxia
  • sensory disturbance
  • constipation
  • vomiting
  • ulcer
  • abdominal cramps
  • loss of appetite
  • hiccups
  • thirst
  • dysphagia
  • tongue disorders
  • insomnia
  • amnesia
  • anxiety
  • disturbance
  • abnormal thinking
  • abnormal behavior
  • rigidity
  • weight loss
  • weight gain
  • facial flushing
  • weakness
  • syncope
  • purpura
  • melena
  • hematoma
  • hemoptysis
  • muscle hemorrhage
  • gingival bleeding
  • anemia
  • cough
  • visual disturbances
  • field of vision impairment
  • dry eyes
  • temporary blindness
  • congestion
  • tinnitus
  • voiding dysfunction
  • polyuria
  • non-protein nitrogen increase
  • uremia
  • increased blood urea nitrogen
  • hypoglycemia
  • hyperuricemia
  • elevated liver enzymes
  • ALT elevation
  • abnormal liver function
  • leg edema
  • arrhythmia
  • bradycardia
  • palpitations
  • contact dermatitis
  • gynecomastia
  • elevated prostate-specific antigen
  • decreased motor function
  • cholecystitis
  • hematemesis
  • spinal hematoma

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly closed container to prevent exposure to air or moisture. Additionally, it is essential to maintain a storage temperature between 1°C and 30°C at room temperature.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.